Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.42), $0.01 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $24.7 million versus the consensus estimate of $26.8 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.